A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
Status:
Not yet recruiting
Trial end date:
2026-06-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the switch from Nivolumab Intravenous (IV) infusions
to Nivolumab Subcutaneous (SC) administration in participants with resected Stage IIIA/B/C/D
or Stage IV melanoma or resected invasive Urothelial Carcinoma (UC) originating in the
bladder who have high risk of recurrence.